Using drug-excipient interactions for siRNA delivery

被引：39

作者：

Bruno, Katharina ^{[1
]}

机构：

[1] Novartis Pharma AG, TRD, Pharmaceut & Analyt Dev PHAD, CH-4057 Basel, Switzerland

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2011年 / 63卷 / 13期

关键词：

Small interfering RNA; siRNA; RNAi; Formulation; Delivery; Clinic; SMALL INTERFERING RNA; IN-VIVO DELIVERY; ENDOTHELIAL GROWTH-FACTOR; INHIBITS TUMOR-GROWTH; DOUBLE-STRANDED-RNA; EFFICIENT DELIVERY; TARGETED DELIVERY; GENE-EXPRESSION; CELLULAR UPTAKE; INTRACELLULAR DELIVERY;

D O I：

10.1016/j.addr.2011.09.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

SiRNA is the trigger of RNA interference, a mechanism discovered in the late 1990s. To release the therapeutic potential of this versatile but large and fragile molecule, excipients are used which either interact by electrostatic interaction, passively encapsulate siRNA or are covalently attached to enable specific and safe delivery of the drug substance. Controlling the delicate balance between protective complexation and release of siRNA at the right point and time is done by understanding excipients-siRNA interactions. These can be lipids, polymers such as PEI, PLGA, Chitosans, Cyclodextrins, as well as aptamers and peptides. This review describes the mechanisms of interaction of the most commonly used siRNA delivery vehicles, and looks at the results of their clinical and preclinical studies. (C) 2011 Elsevier B.V. All rights reserved.

引用

页码：1210 / 1226

页数：17

共 173 条

[1] A combinatorial library of lipid-like materials for delivery of RNAi therapeutics [J].

Akinc, Akin ;

Zumbuehl, Andreas ;

Goldberg, Michael ;

Leshchiner, Elizaveta S. ;

Busini, Valentina ;

Hossain, Naushad ;

Bacallado, Sergio A. ;

Nguyen, David N. ;

Fuller, Jason ;

Alvarez, Rene ;

Borodovsky, Anna ;

Borland, Todd ;

Constien, Rainer ;

de Fougerolles, Antonin ;

Dorkin, J. Robert ;

Jayaprakash, K. Narayanannair ;

Jayaraman, Muthusamy ;

John, Matthias ;

Koteliansky, Victor ;

Manoharan, Muthiah ;

Nechev, Lubomir ;

Qin, June ;

Racie, Timothy ;

Raitcheva, Denitza ;

Rajeev, Kallanthottathil G. ;

Sah, Dinah W. Y. ;

Soutschek, Juergen ;

Toudjarska, Ivanka ;

Vornlocher, Hans-Peter ;

Zimmermann, Tracy S. ;

Langer, Robert ;

Anderson, Daniel G. .

NATURE BIOTECHNOLOGY, 2008, 26 (05) :561-569

[2] Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression [J].

Aleku, Manuela ;

Schulz, Petra ;

Keil, Oliver ;

Santel, Ansgar ;

Schaeper, Ute ;

Dieckhoff, Britta ;

Janke, Oliver ;

Endruschat, Jens ;

Durieux, Birgit ;

Roeder, Nadine ;

Loeffler, Kathrin ;

Lange, Christian ;

Fechtner, Melanie ;

Moepert, Kristin ;

Fisch, Gerald ;

Dames, Sibylle ;

Arnold, Wolfgang ;

Jochims, Karin ;

Giese, Klaus ;

Wiedenmann, Bertram ;

Scholz, Arne ;

Kaufmann, Joerg .

CANCER RESEARCH, 2008, 68 (23) :9788-9798

[3] Tolerance for mutations and chemical modifications in a siRNA [J].

Amarzguioui, M ;

Holen, T ;

Babaie, E ;

Prydz, H .

NUCLEIC ACIDS RESEARCH, 2003, 31 (02) :589-595

[4] Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo [J].

Andaloussi, Samir E. L. ;

Lehto, Taavi ;

Maeger, Imre ;

Rosenthal-Aizman, Katri ;

Oprea, Iulian I. ;

Simonson, Oscar E. ;

Sork, Helena ;

Ezzat, Kariem ;

Copolovici, Dana M. ;

Kurrikoff, Kaido ;

Viola, Joana R. ;

Zaghloul, Eman M. ;

Sillard, Rannar ;

Johansson, Henrik J. ;

Hassane, Fatouma Said ;

Guterstam, Peter ;

Suhorutsenko, Julia ;

Moreno, Pedro M. D. ;

Oskolkov, Nikita ;

Haelldin, Jonas ;

Tedebark, Ulf ;

Metspalu, Andres ;

Lebleu, Bernard ;

Lehtioe, Janne ;

Smith, C. I. Edvard ;

Langel, Uelo .

NUCLEIC ACIDS RESEARCH, 2011, 39 (09) :3972-3987

[5] Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation [J].

Aouadi, Myriam ;

Tesz, Gregory J. ;

Nicoloro, Sarah M. ;

Wang, Mengxi ;

Chouinard, My ;

Soto, Ernesto ;

Ostroff, Gary R. ;

Czech, Michael P. .

NATURE, 2009, 458 (7242) :1180-U116

[6] Design and creation of new nanomaterials for therapeutic RNAi [J].

Baigude, Huricha ;

McCarroll, Joshua ;

Yang, Chao-shun ;

Swain, Pamela M. ;

Rana, Tariq M. .

ACS CHEMICAL BIOLOGY, 2007, 2 (04) :237-241

[7] Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles [J].

Bartlett, Derek W. ;

Davis, Mark E. .

BIOCONJUGATE CHEMISTRY, 2007, 18 (02) :456-468

[8] Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging [J].

Bartlett, Derek W. ;

Su, Helen ;

Hildebrandt, Isabel J. ;

Weber, Wolfgang A. ;

Davis, Mark E. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (39) :15549-15554

[9] Pharmacokinetics in mice of a [H-3]-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid [J].

Bennett, CF ;

Zuckerman, JE ;

Kornbrust, D ;

Sasmor, H ;

Leeds, JM ;

Crooke, ST .

JOURNAL OF CONTROLLED RELEASE, 1996, 41 (1-2) :121-130

[10] Role for a bidentate ribonuclease in the initiation step of RNA interference [J].

Bernstein, E ;

Caudy, AA ;

Hammond, SM ;

Hannon, GJ .

NATURE, 2001, 409 (6818) :363-366

← 1 2 3 4 5 6 7 8 9 10 →